The U.S. FDA conducted the inspection from August 17 to August 21, 2026. At the conclusion of the inspection, the company received four observations in Form 483.
NATCO Pharma has now received the EIR classifying the inspection as Voluntary Action Indicated (VAI).
The company disclosed this information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.







